Thrombin-Activatable Fibrinolysis Inhibitor in Breast Cancer Patients

O. Kaftan\textsuperscript{a} B. Kasapoglu\textsuperscript{a} M. Koroglu\textsuperscript{a} A. Kosar\textsuperscript{b} S.K. Yalcin\textsuperscript{a}

Departments of \textsuperscript{a}Internal Medicine and \textsuperscript{b}Hematology, Fatih University Medical School, Ankara, Turkey

Key Words
Thrombin-activatable fibrinolysis inhibitor • Breast cancer

Introduction

In the United States, more than 180,000 women are diagnosed with breast cancer each year, the second most lethal cancer type in women after lung cancer [1]; breast cancer among women is very prominent as well in both the Middle East and Asia [2]. Unfortunately, a large number of these tumors and some treatment modalities are compounded by risks that increase the mortality and morbidity associated with atherosclerotic complications. In patients with malignant disease, induction of coagulation mechanisms causes increased fibrinolytic function, so such patients show a tendency to coagulation and fibrinolytic disorders [3]. Many factors can affect the coagulation system, including thrombocytosis, elevated D-dimer levels or increased tissue factor levels in cancer patients [4]. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a procarboxypeptidase that is synthesized in the liver and activated by thrombin and the thrombin-thrombomodulin complex that suppresses fibrinolysis by removing carboxy-terminal lysine residues from partially degraded fibrin [5]. TAFI is a proenzyme of the enzyme TAFIa which has a carboxypeptidase activity and a positive feedback mediator at the fibrinolytic cascades [6–8]. However, the importance of TAFI in homeostasis, fibrinolysis and the mechanisms regulated by TAFI are not
completely clarified. TAFI has a thrombotic tendency and can also contribute to atherogenesis as it is involved in the regulation of fibrin stability in the intravascular space [8]. Increased TAFI levels have been associated with several thrombotic conditions including venous thromboembolism [9, 10] and ischemic stroke [11–13]. In addition, increased TAFI has been reported to be a marker of small cell lung cancer (SCC) and distinguishes SCC from non-small cell lung cancer including adenocarcinoma [14]. Evaluation of the levels of TAFI in breast cancer patients may reflect the fibrinolytic capacity of the patients and thus identify those who are prone to cardiovascular disease.

Therefore, the aim of our study was to evaluate the levels of TAFI activity and its relationship with other homeostasis markers in breast cancer patients.

**Subjects and Methods**

Forty-two female subjects with breast cancer and 24 healthy control subjects matched for body mass index were recruited. Informed consent was obtained from each participant. Breast cancer was diagnosed by pathology. The study was approved by the Fatih University School of Medicine Ethics Committee and conducted in accordance with the ethical principles described by the Declaration of Helsinki. Written informed consent was obtained from all participants.

**Study Protocol**

This prospective study was carried out between 2007 and 2008. Fasting blood samples were drawn from large antecubital veins of the forearm, without interruption of venous flow for TAFI. Other homeostasis tests performed were: prothrombin time (PT); activated partial thromboplastin time (aPTT); fibrinogen; complete blood count, blood urea nitrogen, calcium, γ-glutamyl transferase (GGT), lactate dehydrogenase (LDH), aspartate amino transferase (AST) and alanine amino transferase (ALT).

**Assessments**

Blood samples for TAFI, PT, aPTT, fibrinogen and D-dimer were centrifuged within 30 min of collection, at 4°C for 20 min at 3,000 rpm. The supernatant plasma samples were separated and transferred into polypropylene tubes and stored up to 1 month at −30°C. Blood urea nitrogen, calcium, GGT, LDH, AST and ALT were determined using an autoanalyzer (Hitachi 912; Roche) with the company’s original kits. PT and aPTT were assessed with a coagulometer, and fibrinogen levels were assessed with a nephelometer. Plasma TAFI activity was measured by a chromogenic assay (Imulclone TAFI, American Diagnostica Inc., Stamford, Conn., USA). Complete blood counts were measured with Coulter MaxM (Philadelphia, Pa., USA). Blood pressure was measured using a mercury sphygmomanometer after giving each participant a 5-min rest period. The means of two measurements of systolic and diastolic blood pressures were taken and recorded before withdrawing blood.

**Results**

The TAFI levels were 79.5 ± 15.5 and 39.3 ± 12.1, in patient and control groups, respectively (table 1). The difference was statistically significant (p < 0.001). The TAFI levels were significantly higher in the patient group, which may reflect the thrombotic state. Florian-Kujawski et al. [15] showed increases in both PAI-1 and TAFI levels in cancer patients, which may cause the fibrinolytic deficiency. Similarly, in

| Parameter       | Patients  | Controls | p value |
|-----------------|-----------|----------|---------|
| TAFI            | 79.5 ± 15.5 | 39.3 ± 12.1 | <0.001 |
| PT              | 11.2 ± 1.2  | 11.4 ± 1.6  | >0.05   |
| aPTT            | 31.2 ± 5.5  | 32.4 ± 5.6  | >0.05   |
| D-dimer, ng/ml  | 531 ± 199   | 141 ± 91    | <0.001  |
| Fibrinogen, mg/dl | 504 ± 224  | 293 ± 100   | <0.001  |
| LDH, U/l        | 184.4 ± 30.2| 153.1 ± 36.3| >0.05   |

**Statistical Analysis**

All statistical analyses were performed using the SPSS program, version 11.5 (SPSS Inc., Chicago, Ill., USA). Results are given as means ± standard deviation. Within and between group differences were analyzed by Student’s paired and unpaired t tests. Analysis of variance was used to compare multiple-group means. A p value <0.05 was considered statistically significant.

**Discussion**

In our study, TAFI and fibrinogen levels were significantly higher in the patient group, which may reflect the thrombotic state. Florian-Kujawski et al. [15] showed increases in both PAI-1 and TAFI levels in cancer patients, which may cause the fibrinolytic deficiency. Similarly, in
a study by Hataji et al. [14], TAFI levels were found to be increased in SCC patients. On the other hand, among patients with acute promyelocytic leukemia, reduced TAFI activity has been observed [16]. Interestingly, Reijerkerk et al. [17] showed that TAFI deficiency did not affect the formation and growth of tumor and tumor metastasis in mice in any tumor model. Overall, these data indicate that TAFI levels may be cancer type specific.

Cancer is a well-described prothrombotic state [18–20] and thromboembolic events are the second leading cause of death in patients with malignancies who have an 11% lifetime risk of thromboembolism [18, 20]. Because of the high prevalence of breast cancer, its complications are of high clinical relevance. Patients with malignancies display a wide range of coagulation disorders from asymptomatic laboratory changes to massive thromboembolism and disseminated intravascular coagulation. Approximately 50% of all cancer patients exhibit abnormalities in coagulation tests and 90% of these patients have metastatic disease [21–24]. Thrombocytosis and increased plasma fibrinogen levels are the most common abnormalities. Also, in patients with malignancies, immobilization, surgical operations, infections, vascular endothelial injury induced by chemotherapeutic agents and abnormalities of the blood coagulation system contribute to thrombophilic and hypercoagulative states. Up to 15% of patients with cancer present with venous thromboembolism during the course of their disease. Approximately 5% of breast cancer patients have thrombotic complications while on chemotherapy [3]. The increased levels of TAFI and fibrinogen found in our study may explain the thrombotic state of breast cancer patients.

Upon activation by thrombin or plasma, TAFI is converted to an enzyme (TAFIa), which acts as an inhibitor of tPA-dependent fibrinolysis. The most physiological activator of TAFI is thrombin, which increases its efficiency 1,000-fold. TAFI can also work alone or as a complex with thrombomodulin. Interestingly, it is believed that TAFI activation by the thrombin-thrombomodulin complex occurs on endothelial surfaces adjacent to the hemostatic plug and protects from fibrinolysis outside of the fibrin matrix. On the other hand, TAFI activation by thrombin alone takes place within the hemostatic plug and serves to downregulate fibrinolysis induced by tPA incorporated into the fibrin plug [8].

In addition, the D-dimer level of the patient group in our study was statistically significantly higher than that of the control group. This finding is also compatible with our other findings since plasma D-dimer level is a marker of hypercoagulability and the fibrinolytic system. Similarly, Yigit et al. [25] found increased plasma D-dimer and fibrinogen levels in newly diagnosed breast cancer patients compared with controls. Moreover in a recent study, the plasma D-dimer level was found to be statistically significantly higher in 32 patients with breast cancer than in 43 healthy women [26].

One of the limitations of this study is that the patients were not grouped according to disease stage or the presence of metastases. That would be a goal of future works since this study focused on determining TAFI levels in breast cancer patients independent of tumor stage.

**Conclusion**

We demonstrated that TAFI levels were higher in breast cancer patients than in healthy women. Since TAFI is associated with a thrombotic tendency and may play a role in hypercoagulability states, it may be an important complicating factor in breast malignancies that should be evaluated during patient follow-up. Further studies are necessary to elucidate TAFI levels and their effects on metastatic disease and patient prognosis.

**References**

1 United States National Institutes of Health, National Cancer Institute Breast Cancer 2007 report.
2 Dey S, Soliman AS: Cancer in the global health era: opportunities for the Middle East and Asia. Asia Pac J Public Health 2010;22: 75–82.
3 Caine GJ, Stonelake PS, Rea D, Lip GYH: Coagulopathic complications in breast cancer. Cancer 2003;98:1578–1586.
4 Ay C, Pabinger I: Tests predictive of thrombosis in cancer. Thromb Res 2010;125(suppl 2):S12–S15.
5 Wang W, Boffa PB, Bajzar L, Walker JB, Nesheim ME: A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998;273:27176–27181.
6 Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Strömqvist M, Hendriks D, Hamsten A: Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000;84:364–368.
7 Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995;270:14477–14484.
8 Redlitz A, Tan AK, Eaton DL, Plow EF: Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995;96:2534–2538.

9 Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelon Y, Alessi MC: Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000;95:2855–2859.

10 Van Tilburg NH, Rosendal FR, Bertina RM: Thrombin-activatable fibrinolysis. Blood 2000;95:2855–2859.

11 Eicheinger S, Schönauer V, Weltermann A, Minar E, Bialonczyk C, Hirsch M, Schneider B, Quehenberger P, Kyrle PA: Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004;103:3773–3776.

12 Leebeek FW, van Goor MP, Guimares AHC, Brouwers GJ, deMaat MP, Dippel DW, Rijken D: High functional levels of thrombin-activatable fibrinolysis are associated with increased risk of first ischemic stroke. J Thromb Haemost 2005;3:2211–2218.

13 Montaner J, Ribo M, Monasterio J, Molina CA, Alvarez-Sabin J: Thrombin-activatable fibrinolysis inhibitor antigen levels acute phase of ischemic stroke. Stroke 2003;34:1038–1040.

14 Hataji O, Taguchi O, Gabazza EC, Yuda H, D’Alessandro-Gabazza CN, Fujimoto H, Nishii Y, Hayashi T, Suzuki K, Adachi Y: Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol 2004;76:214–219.

15 Florian-Kujawski MR, Hoppenstead D, Iqbal O, Demir M, Tobu M, Fareed D, Fareed J: Role of PAI-1 and TAFI in the mediation of fibrinolytic deficit in cancer patients: 2004 ASCO Annu Meet Proc (Post-Meeting Edition). J Clin Oncol 2004;22(suppl):9727.

16 Meijers JC, Oudijk EJ, Mosnier LO, Bos R, Bouma BN, Nieuwenhuis HK, Fijnheer R: Reduced activity of TAFI (thrombinactivatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000;108:518–523.

17 Reijerkerk A, Meijers JC, Havik SR, Bouma BN, Voest EE, Gebbink MF: Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. J Thromb Haemost 2004;2:769–779.

18 Rickles FR, Edwards RL: Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983;62:14–31.

19 Caine GJ, Stonelake PS, Lip GY, Kehoe ST: Hypercoagulable state of malignancy. Neoplasia 2002;4:465–473.

20 Donati MB: Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995;74:278–281.

21 Lip GY, Chin BS, Blann AD: Cancer and prothrombotic state. Lancet Oncol 2002;3:27–34.

22 Goad KE, Gralnick HR: Coagulation disorders in cancer. Hematol Oncol Clin North Am 1996;10:457–484.

23 Edwards RL, Rickles FR, Moritz TE: Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987;88:596–602.

24 Luzatto G, Schafer AI: The prethrombotic state in cancer. Semin Oncol 1990;17:147–159.

25 Yigit E, Gönülloğu G, Yücel I, Turgut M, Erdem D, Cakar B: Relation between hemostatic parameters and prognostic/predictive factors in breast cancer. Eur J Intern Med 2008;19:602–607.

26 Batschauer AP, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LM, Fernandes AP, Gomes KB, Carvalho MG: D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol 2010;21:1267–1272.